Publications by authors named "M L Porrino-Bustamante"
Low-dose oral minoxidil for frontal fibrosing alopecia: a 122-patient case series.
Actas Dermosifiliogr
November 2024
Article Synopsis
- * Out of 122 patients, 45.1% reported subjective improvements in hair density at the frontotemporal hairline, with varying degrees of improvement noted.
- * While 57.4% of patients saw overall hair density improvements, 33.6% experienced adverse effects, primarily hypertrichosis; however, the findings suggest that oral minoxidil can enhance hair and eyebrow growth in FFA patients.
Background: Androgenetic alopecia (AGA) is common. While topical minoxidil remains the only FDA-approved therapeutic for AGA, its efficacy is limited in stimulating clinically significant hair regrowth over the longer term. Oral minoxidil, which is used off-label, is a promising alternative; however, its effectiveness and underlying mechanisms warrant further investigation.
View Article and Find Full Text PDFArticle Synopsis
- In Spain, medical graduates take a state exam to select specialities, with dermatology requiring 4 years of hospital training, and feedback from residents is crucial for improvement.
- A survey of 54 dermatology residents revealed that while most found clinical sessions beneficial, they identified laser and esthetics training as significant gaps in their education.
- The study highlights residents' aspirations towards research, with a notable interest in pursuing PhDs, signaling evolving trends and needs in dermatology training.
Background And Objective: Systemic adverse effects (AE) are a major concern of low-dose oral minoxidil (LDOM) treatment, especially in patients with arterial hypertension or arrhythmia. The objective of this study was to evaluate the safety of LDOM in patients with hypertension or arrhythmia.
Patients And Methods: Retrospective multicenter study of patients with hypertension or arrhythmia treated with LDOM for any type of alopecia.